Real Time Search
CES A80 :
CES 120 :
Total Turn.

Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital

2024-04-23 10:52:00

- Series A financing to advance clinical development of lead candidate RLS-1496 into Phase 1 studies this year in chronic atopic dermatitis and chronic psoriasis.

SUNNYVALE, Calif.--()--Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, today announced the closing of a $40M Series A financing round. The round was led by Khosla Ventures and Ahren Innovation Capital, with participation from Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital, LongeVC, Italian Angels for Growth (IAG), and other investors.

The funding will be used to advance the company’s lead candidate RLS-1496 in chronic atopic dermatitis and chronic psoriasis, which will be entering Phase 1 studies. Rubedo is also developing additional therapies that selectively target senescent cells in pulmonary diseases with significant unmet medical need, such as idiopathic pulmonary fibrosis (IPF), with a program recipient of a substantial CIRM grant last year.

“We’re delighted to attract this top-tier syndicate co-led by Khosla Ventures and Ahren Innovation Capital. This significant influx of financing will allow us to advance our first clinical candidate into human studies,” said Marco Quarta, CEO & Co-Founder of Rubedo Life Sciences.

“As people live longer, improving quality of life is paramount,” said Alex Morgan, Partner, Khosla Ventures. “Rubedo is targeting senescent, or aging, cells that drive age-related diseases. This first trial can bring us another step closer to achieving better healthspan.”

“Our mission is to invest in transformational companies that will change the world for the better, serving vast markets,” said Alice Newcombe Ellis, Founding & General Partner, Ahren Innovation Capital. “We believe that Rubedo’s transformative approach to targeting senescent cells is an impressive step towards the development of chronic age-related therapies, which will advance biotech from treatment to prevention or disease reversal.”

“The significant experience and capital that our investors bring to Rubedo will help the company rapidly advance our programs,” said Ali Siam, Chief Business Officer, Rubedo Life Sciences. “We look forward to working with these leaders, whose vast experience in clinical development will be invaluable as we enter the next phase of growth at Rubedo.”

Rubedo’s Alembic™ drug discovery platform enables the identification of specific druggable targets for development into therapeutics that selectively target pathologic cells, such as various types of senescent cells, that drive the process of biological aging. Senescence is the process by which a cell ages and permanently stops dividing but does not die. Any cell can potentially become senescent. Over time, large numbers of senescent cells can build up in tissues throughout the body and release pathologic factors. When they reach a critical mass, they cause chronic inflammation and damage leading to fibrosis and tissue degeneration which drive many age-related diseases.

About Rubedo Life Sciences

Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target various types of senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, technology, and life sciences, with expertise in drug development and commercialization from both large pharma and leading biotech companies. The company is based in Sunnyvale, CA. For additional information, visit


Kimberly Ha
KKH Advisors

Rubedo Life Sciences scientists. Photo credit: ALESSANDRO GANDOLFI


Interfax Business Wire

Oaktree Assumes Ownership of Inter Milan
Medscape Education and KDIGO Nephrology Collaboration Accelerates Improvements to Patient Care
NetJets Announces Collaboration With Acclaimed Artist Silvère Jarrosson
SSA Marine Appoints Nicolas Gauthier as President of the Company’s Global Container Division
QPS Expands Clinic in Miami, Florida to Accommodate Increasing Demand for Obesity Trials
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
Power Integrations Launches Single-Board Plug-and-Play Gate Drivers for 1.2 kV to 2.3 kV “New Dual” IGBT Modules
Eaton Introduces 48-Volt DC/DC Converter Designed for Harsh Environments
Leading Pharmaceutical Company Selects Kinaxis to Cure Supply Chain Headaches
Lenovo Supercharges Next Gen Copilot+ PCs with Latest Yoga Slim 7x and ThinkPad T14s Gen 6
Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally
Equip Super Completes Transition to Northern Trust for Asset Servicing Solutions
GIGABYTE Showcases a Whole Lot of Computing Power at COMPUTEX, Taking the AI-driven New Evolution Head-On
MultiBank Group Revolutionizes Finance with the Launch of MEX Exchange, the First Global ECN in the BRICS & GCC
Carestream Introduces Image Suite MR 10 Software to Enhance Imaging Experience for CR and DR Imaging Systems
Zycus Unleashes Next-Generation Procurement Power with GenAI Innovations at Horizon 2024
Transphorm’s SuperGaN at PCIM 2024: Surpassing SiC and e-mode GaN Capabilities in High Power Systems
Applications Software Technology Acquires Symatrix to Accelerate Global Expansion in Oracle Cloud Services
Francesco Buquicchio Named Next CEO of Egon Zehnder
Hithium and Maxxen cooperate in exclusive strategic partnership in Türkiye
Back to Top